AU771548B2 - Method for detecting syphilis using synthetic antigens - Google Patents
Method for detecting syphilis using synthetic antigens Download PDFInfo
- Publication number
- AU771548B2 AU771548B2 AU54756/00A AU5475600A AU771548B2 AU 771548 B2 AU771548 B2 AU 771548B2 AU 54756/00 A AU54756/00 A AU 54756/00A AU 5475600 A AU5475600 A AU 5475600A AU 771548 B2 AU771548 B2 AU 771548B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- approximately
- antigen
- cardiolipin
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000006379 syphilis Diseases 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 51
- 108010008038 Synthetic Vaccines Proteins 0.000 title description 9
- 239000000427 antigen Substances 0.000 claims abstract description 142
- 102000036639 antigens Human genes 0.000 claims abstract description 135
- 108091007433 antigens Proteins 0.000 claims abstract description 135
- 239000000203 mixture Substances 0.000 claims abstract description 101
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 43
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims abstract description 37
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 30
- 238000001514 detection method Methods 0.000 claims abstract description 29
- 238000012360 testing method Methods 0.000 claims description 71
- SDCJNZZAOLRVCP-GTOSQJSUSA-N tetramyristoyl cardiolipin Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCC)COP(O)(=O)OCC(O)COP(O)(=O)OC[C@H](OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC SDCJNZZAOLRVCP-GTOSQJSUSA-N 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 14
- 238000005189 flocculation Methods 0.000 claims description 9
- 230000016615 flocculation Effects 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 230000004520 agglutination Effects 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 35
- 239000000787 lecithin Substances 0.000 abstract description 32
- 241000589884 Treponema pallidum Species 0.000 abstract description 31
- 229940067606 lecithin Drugs 0.000 abstract description 31
- 235000010445 lecithin Nutrition 0.000 abstract description 29
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract description 28
- 238000003018 immunoassay Methods 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 238000003556 assay Methods 0.000 description 38
- 239000000523 sample Substances 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 20
- 238000012128 rapid plasma reagin Methods 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 230000003429 anti-cardiolipin effect Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 208000002040 neurosyphilis Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 208000003796 chancre Diseases 0.000 description 6
- 238000010835 comparative analysis Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 208000008306 Latent Syphilis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 201000006901 congenital syphilis Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 208000009090 primary syphilis Diseases 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 206010056873 tertiary syphilis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 201000000860 Secondary syphilis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- ZLFVRXUOSPRRKQ-UHFFFAOYSA-N chembl2138372 Chemical compound [O-][N+](=O)C1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 ZLFVRXUOSPRRKQ-UHFFFAOYSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 238000001446 dark-field microscopy Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000014479 late latent syphilis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 201000006088 tertiary neurosyphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13819299P | 1999-06-09 | 1999-06-09 | |
| US60/138192 | 1999-06-09 | ||
| PCT/US2000/015828 WO2000075666A1 (en) | 1999-06-09 | 2000-06-08 | Method for detecting syphilis using synthetic antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5475600A AU5475600A (en) | 2000-12-28 |
| AU771548B2 true AU771548B2 (en) | 2004-03-25 |
Family
ID=22480887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU54756/00A Expired AU771548B2 (en) | 1999-06-09 | 2000-06-08 | Method for detecting syphilis using synthetic antigens |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1185872B1 (enExample) |
| JP (1) | JP4531314B2 (enExample) |
| CN (1) | CN1195986C (enExample) |
| AT (1) | ATE316245T1 (enExample) |
| AU (1) | AU771548B2 (enExample) |
| BR (1) | BRPI0011449B8 (enExample) |
| CA (1) | CA2375448C (enExample) |
| DE (1) | DE60025605T2 (enExample) |
| RU (1) | RU2244933C2 (enExample) |
| WO (1) | WO2000075666A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10250368A1 (de) * | 2002-10-29 | 2004-05-19 | Viramed Biotech Ag | Mittel und Verfahren zur Diagnose einer Treponemainfektion |
| RU2270450C1 (ru) * | 2004-08-20 | 2006-02-20 | Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия Министерства Здравоохранения Российской Федерации" | Способ диагностики сифилиса |
| US8148057B2 (en) | 2005-06-21 | 2012-04-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Methods, immunoassays and devices for detection of anti-lipoidal antibodies |
| AP2787A (en) | 2005-06-21 | 2013-10-31 | Us Gov Health & Human Serv | Methods, immunoassays and devices for detection ofanti-lipoidal antibodies |
| WO2007061793A2 (en) * | 2005-11-18 | 2007-05-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SCIENCES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Modified cardiolipin and uses therefor |
| US8778619B2 (en) | 2005-11-18 | 2014-07-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oxidized cardiolipin and uses to detect cardiolipin antibodies |
| JP4629563B2 (ja) * | 2005-12-07 | 2011-02-09 | 積水メディカル株式会社 | 抗リン脂質抗体測定試薬 |
| WO2007066731A1 (ja) * | 2005-12-07 | 2007-06-14 | Sekisui Medical Co., Ltd. | 抗リン脂質抗体測定試薬及び抗トレポネーマ・パリダム抗体測定試薬 |
| RU2327170C2 (ru) * | 2006-02-27 | 2008-06-20 | Закрытое акционерное общество "ДиТест" | Способ комплексной диагностики вирусного гепатита в, вирусного гепатита с, вич-инфекции и сифилиса |
| RU2394496C1 (ru) * | 2009-03-11 | 2010-07-20 | Федеральное Государственное Учреждение "Государственный Научный Центр Дерматовенерологии Федерального Агентства По Высокотехнологичной Медицинской Помощи" | Способ диагностики сифилиса путем одновременного определения реагиновых и трепонемоспецифических антител к t.pallidum на микроскопных альдегидных слайдах |
| RU2421730C1 (ru) * | 2010-04-09 | 2011-06-20 | Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" | Способ диагностики раннего врожденного сифилиса скрытого |
| CN102095861A (zh) * | 2011-01-25 | 2011-06-15 | 厦门大学附属中山医院 | 梅毒特异性总抗体和心磷脂抗体免疫印迹试剂盒及其制备 |
| RU2474820C2 (ru) * | 2011-04-11 | 2013-02-10 | Виктория Олеговна Пожарская | Способ контроля эффективности лечения сифилиса |
| US8945827B2 (en) | 2013-03-13 | 2015-02-03 | Awareness Technology, Inc. | Serological methods and diagnostic tests for syphilis antibodies |
| CN104049081B (zh) * | 2013-03-13 | 2016-03-09 | 意识科技股份有限公司 | 针对梅毒抗体的血清学方法和诊断测试 |
| GB201400819D0 (en) * | 2014-01-17 | 2014-03-05 | Sec Dep For Health The | Mycobacterial antigen composition |
| CN107533060B (zh) * | 2015-03-10 | 2019-11-05 | 生物辐射实验室股份有限公司 | 组合密螺旋体和非密螺旋体梅毒测试 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1053504A (enExample) * | 1964-03-17 | 1967-01-04 | ||
| US4307074A (en) * | 1978-09-18 | 1981-12-22 | Hoffmann-La Roche Inc. | Novel reagent |
-
2000
- 2000-06-08 DE DE60025605T patent/DE60025605T2/de not_active Expired - Lifetime
- 2000-06-08 CN CNB008085404A patent/CN1195986C/zh not_active Expired - Lifetime
- 2000-06-08 JP JP2001501890A patent/JP4531314B2/ja not_active Expired - Lifetime
- 2000-06-08 WO PCT/US2000/015828 patent/WO2000075666A1/en not_active Ceased
- 2000-06-08 EP EP00939708A patent/EP1185872B1/en not_active Expired - Lifetime
- 2000-06-08 CA CA002375448A patent/CA2375448C/en not_active Expired - Lifetime
- 2000-06-08 BR BRPI0011449A patent/BRPI0011449B8/pt not_active IP Right Cessation
- 2000-06-08 AT AT00939708T patent/ATE316245T1/de active
- 2000-06-08 RU RU2001135795/15A patent/RU2244933C2/ru active
- 2000-06-08 AU AU54756/00A patent/AU771548B2/en not_active Expired
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1053504A (enExample) * | 1964-03-17 | 1967-01-04 | ||
| US4307074A (en) * | 1978-09-18 | 1981-12-22 | Hoffmann-La Roche Inc. | Novel reagent |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60025605D1 (de) | 2006-04-06 |
| BR0011449B1 (pt) | 2013-12-03 |
| EP1185872B1 (en) | 2006-01-18 |
| RU2244933C2 (ru) | 2005-01-20 |
| AU5475600A (en) | 2000-12-28 |
| CN1195986C (zh) | 2005-04-06 |
| ATE316245T1 (de) | 2006-02-15 |
| CN1353815A (zh) | 2002-06-12 |
| CA2375448C (en) | 2009-04-07 |
| WO2000075666A1 (en) | 2000-12-14 |
| BRPI0011449B8 (pt) | 2021-05-25 |
| DE60025605T2 (de) | 2006-11-09 |
| JP2003501662A (ja) | 2003-01-14 |
| CA2375448A1 (en) | 2000-12-14 |
| EP1185872A1 (en) | 2002-03-13 |
| JP4531314B2 (ja) | 2010-08-25 |
| BR0011449A (pt) | 2002-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU771548B2 (en) | Method for detecting syphilis using synthetic antigens | |
| US5187065A (en) | Method and materials for detecting lyme disease | |
| Nandwani et al. | Are you sure it's syphilis? A review of false positive serology | |
| Lappalainen et al. | Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG | |
| AU2012207267C1 (en) | Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease | |
| Selva-O’Callaghan et al. | IgA anticardiolipin antibodies–relation with other antiphospholipid antibodies and clinical significance | |
| WO1995033995A1 (en) | Method and kit for detecting antibodies | |
| Devi et al. | A new serum hydatid antigen detection test for diagnosis of cystic echinococcosis | |
| US6815173B1 (en) | Method for detecting syphilis using synthetic antigents | |
| US4618588A (en) | Reagent and merchandising kit for use in the diagnosis of syphilis and preparation thereof | |
| EP1240519B1 (en) | Compositions and methods for detecting treponema pallidum | |
| Fischman | Flocculation tests in hydatid disease | |
| Castro et al. | Use of synthetic cardiolipin and lecithin in the antigen used by the venereal disease research laboratory test for serodiagnosis of syphilis | |
| WO1987006620A1 (en) | Diagnostic kit for sexually transmitted diseases | |
| CN104330566B (zh) | 梅毒试纸条及其制备方法、梅毒检测卡及其制备方法 | |
| Ho | Review on serologic diagnosis of syphilis | |
| JP3547729B2 (ja) | アッセイ | |
| Sato et al. | Treponema pallidum specific IgM haemagglutination test for serodiagnosis of syphilis. | |
| RU2846805C1 (ru) | Иммунохроматографическая тест-система для неинвазивного определения уровня антиовариальных антител в биологической жидкости и способ определения антиовариальных антител с помощью тест-полоски, входящей в тест-систему | |
| Chiabi et al. | Diagnosis of neonatal sepsis in low resource settings: C-reactive protein or procalcitonin? | |
| JPH05312808A (ja) | 脂質抗原を用いた免疫検査法 | |
| Samuel et al. | Serodiagnostic tests in tuberculosis | |
| Al-Haddad | Serodiagnosis of Infectious Diseases among Patients admitted to Ibn Sina Central Teaching Hospital in Al-Mukalla City-Yemen | |
| JPH06213889A (ja) | 免疫血清診断法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |